Can a painkiller blocker boost cancer immunotherapy?
NCT ID NCT07662720
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether adding axelopran—a drug that blocks opioid effects on the immune system—can help pembrolizumab (an immunotherapy) work better in people with advanced head and neck cancer who take opioids for pain. About 18 participants will receive both drugs and be monitored for safety and tumor response. The goal is to see if counteracting opioid-related immune suppression improves treatment outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
axelopran (a drug that blocks opioid effects on the immune system) and pembrolizumab (an immunotherapy drug)
What this could lead to
If it works, this could improve how well immunotherapy fights head and neck cancer in patients who need opioids for pain.
What could go wrong
This is a very early, small trial with only 18 people. It may not show benefit, and side effects from combining the drugs are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) - RECURRENT/METASTATIC (R/M) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.